Targeting pancreatic cancer with a new dual inhibitor treatment
Combating Resistance of Pancreatic Cancer with a First-in-Class Dual Targeted PI3K/EGFR Inhibitor
This study is testing a new treatment for pancreatic cancer that combines a special drug with other therapies to see if it can work better than current options, with the hope of helping patients live longer and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10652462 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for pancreatic cancer, which is notoriously difficult to treat. The approach involves a first-in-class dual inhibitor that targets both PI3K and EGFR pathways, aiming to overcome the resistance seen with current therapies. The study will optimize the effectiveness of this new drug, MTX-211, and explore its use in combination with other treatments, such as MEK inhibitors and immune checkpoint inhibitors. Patients may benefit from improved treatment options that could enhance survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS-mutant pancreatic cancer who have limited treatment options.
Not a fit: Patients with non-KRAS-mutant pancreatic cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While the specific dual inhibitor approach is novel, similar strategies targeting the RAS signaling pathway have shown promise in other cancer types.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Leopold, Judith S — University of Michigan at Ann Arbor
- Study coordinator: Leopold, Judith S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.